Earnings Releases·Nov 3, 2026, 4:12 PM ET

Amwell — Third Quarter 2026 Earnings Summary

Total revenue for the quarter ended September 30, 2026, reached $49.0 million, exceeding guidance, while nine-month revenue declined to $155.9 million from $194.0 million in the prior year period; net loss narrowed significantly to $30.9 million for the nine months from $69.8 million previously.
The Company raised its full-year 2026 revenue outlook to $204–$206 million and adjusted EBITDA outlook to ($8)–($7) million, with Q4 revenue guidance set at $48–$50 million and adjusted EBITDA expected between $0 and $1 million.
Amwell Medical Group (AMG) visit revenue totaled $23.7 million for the quarter, contributing to a gross margin of 53%, while the company recognized a $7.0 million net gain on the divestiture of its APC business during the nine-month period.
Management reiterated the objective to achieve positive cash flow from operations in Q4 2026, supported by a reduction in net cash used in operating activities to $1.9 million for the nine months compared to $48.6 million in the prior year.